Last reviewed · How we verify

Prevention of Maternal-Fetal Transmission of HIV — Treatment Landscape & Competitive Intelligence

Prevention of Maternal-Fetal Transmission of HIV (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prevention of Maternal-Fetal Transmission of HIV, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Retrovir ZIDOVUDINE GSK Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Thymidine kinase, cytosolic 1987-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. GSK · 1 drug in Prevention of Maternal-Fetal Transmission of HIV

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of Maternal-Fetal Transmission of HIV:

Cite this brief

Drug Landscape (2026). Prevention of Maternal-Fetal Transmission of HIV — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-maternal-fetal-transmission-of-hiv. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing